VIRGINIA RETIREMENT SYSTEMS ET Al Invests $27.85 Million in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• The Virginia Retirement Systems has invested approximately $27.85 million in Regeneron Pharmaceuticals, purchasing 53,054 shares in the second quarter.
• Regeneron recently reported $12.89 earnings per share, significantly surpassing analysts' expectations of $8.43, with quarterly revenue also exceeding estimates at $3.68 billion.
• The company's stock has a consensus rating of "Moderate Buy" and a target price estimate of $817.88, with recent upgrades from various analysts.

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 53,054 shares of the biopharmaceutical company's stock, valued at approximately $27,853,000.

Other large investors have also modified their holdings of the company. E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 344.4% during the first quarter. E Fund Management Hong Kong Co. Ltd. now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 31 shares during the last quarter. Activest Wealth Management grew its stake in shares of Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 21 shares during the last quarter. Costello Asset Management INC purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Saudi Central Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $27,000. Finally, Colonial Trust Advisors purchased a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

NASDAQ:REGN opened at $578.05 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. The firm has a market cap of $61.27 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.80 and a beta of 0.31. The company has a 50 day moving average price of $574.64 and a 200-day moving average price of $562.12. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $1,002.69.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $11.56 EPS. Equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Monday, August 18th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Monday, August 18th. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on REGN shares. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Sanford C. Bernstein lifted their target price on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Raymond James Financial raised Regeneron Pharmaceuticals to a "moderate buy" rating in a report on Tuesday, September 2nd. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.